Sobi Set to Purchase Arthrosi Therapeutics
Acquisition Details: Swedish Orphan Biovitrum AB (SOBI) has agreed to acquire Arthrosi Therapeutics for up to $1.5 billion, which includes an upfront payment of $950 million and contingent payments of up to $550 million.
Strategic Importance: The acquisition aims to enhance Sobi's gout treatment portfolio by adding pozdeutinurad, an investigational drug for managing progressive and tophaceous gout, currently in Phase 3 clinical studies.
CEO's Statement: Sobi's CEO, Guido Oelkers, highlighted the potential of pozdeutinurad to become a preferred therapy for patients with unresolved gout symptoms, projecting significant growth for the company through the mid-2030s.
Future Collaboration: Arthrosi will continue its partnership with Viva Biotech for the supply of active pharmaceutical ingredients, indicating ongoing business cooperation post-acquisition.
About the author









